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INTRODUCTION
This r esearch proposal has t wo primary obj ectives w hich are t o (1) i ncrease F IU i nvestigators' r esearch expertise and competitive abi lity t o succeed as i ndependent br east can cer r esearchers; and (2) t o execute research with the p romise of identifying molecular causes of b reast tumor resistance to ant i-estrogen therapy. We pr oposed t o i nvestigate how r eactive ox ygen s pecies ( ROS)-induced redox s ignaling p athways i n br east cancer cells m ay contribute t o molecular m echanisms of ant iestrogen resistance. Our hypothesis i s t hat t he conversion of breast tumors to a tamoxifen-resistant phenotype is associated with a progressive shift towards a pro-oxidant environment of cells as a result of oxidative stress. We postulate that excess ROS levels induce both CDC25A and c hange p27 phos phorylation pr omoting t he l oss of i ts inhibitory f unction a nd l eading t o antiestrogen resistance. We will investigate whether reducing the oxidative environment of breast cancer cells will r estore the a nti-proliferative action of t amoxifen a nd ot her a ntiestrogens b y r epressing CDC25A and altering p27 phosphorylation and restoring p27 function.
BODY
To extend and enhance the FIU investigators' skills to increase their research expertise and competitive ability to succeed as independent breast cancer researchers, we proposed to conduct the following training tasks each year during the 4yr period of this project: i) To conduct onsite weekly lab meetings in which FIU investigators and trainees report research data, trouble-shoot, and plan experiments; ii) To meet every other week onsite to facilitate c oordination of the pr oject; iii) T o participate in the mont hly BFBCI S cientist S eminars a t the University of M iami t o broaden FIU i nvestigators know ledge of t he m ost c urrent c linical research i n br east cancer; i v) T o establish an Invited E xpert B reast C ancer R esearch Seminar S eries at t he FIU campus. v) T o promote breast cancer research at the FIU campus, FIU/BFBCI training program will sponsor an annual onsite Breast Cancer Workshop. vi) To participate in the grant writing workshop entitled "The Molecular Mechanisms of B reast C ancer"; and vii) T o pr epare a w ritten qua rterly progress r eport of on going a ctivities, a nd c ompile them together to prepare the annual progress report.
In order to meet the objective of training
The training tasks and their progress: Task 1, we have been holding weekly lab meetings on every Monday at 9:30 am at the FIU campus in HLS bldg Rm 596. Since the start date of this grant, both pre-doctoral students and f aculty have participated in the weekly l ab meetings i n which w e r eport the results a nd f rom t he interpretation of the data we plan experiments for the upcoming week. We have continued to meet since the last annual pr ogress r eport da te. To achieve Task 2, a ll t hree F IU i nvestigators ha ve be en i nvolved i n bi weekly discussions t o f acilitate t he f orward pr ogress o f t his pr oposal a t F IU. T o a chieve Task 3, all t hree F IU investigators a nd t hree pre-doctoral s tudent t rainees ha ve pa rticipated i n BFBCI S cientist S eminars a t the University of Miami since June 2007. Drs. Roy and Felty as Dr. S huk-mei H o, P rofessor a nd C hair o f t he D ept. of E nvironmental Health a t t he U niversity of C incinnati. Title of Talk: Emerging Epigenetic Issues and Hormonal Cancer.
Dr. Sushanta Banerjee, Director of C ancer R esearch U nit, VA H ospital Kansas City; a nd P rofessor i n t he Division of H ematology a nd O ncology a t t he Kansas U niversity M edical S chool. Title of T alk: " CCN5 signaling in Regulation of microenvironment of Breast Cancer".
Task 5, we have continued to hold the Annual Breast Cancer Symposium. The first symposium was held on July 23, 2008 at the FIU campus GC Bldg. Rm 243. The symposium was highly successful with over 15 posters and presentations from FIU graduate students and faculty as well as participants from Florida Atlantic University and 44 attendees. Our guest speaker Dr. Linda Malkas is the Vera Bradley Chair of Oncology and Professor in the Dept. of Medicine at Indiana University. She did an outstanding job with her presentation titled: "Cancer Biomarkers & Target Discovery". This symposium provided the first ever opportunity for FIU faculty and graduate s tudents from different disciplines (i.e. Biomedical Engineering, S chool of S ocial Work, etc) to meet and establish future collaborations. We have scheduled the 2 nd symposium for June 25, 200 9. As part of training Task 6, one of our FIU faculty participated in the NIH grant training workshop. For training Task 7 we continue to collect records of our activities in MS PowerPoint files which we use to prepare the annual report.
Challenges:
One of ou r pre-doctoral trainees, Michelle N yguen, who joined us in August 2007 has made the decision to pursue her Master's degree. We are currently searching for an appropriate pre-doctoral student to fill this vacancy.
In summary, we have continued all training tasks we proposed to carry out in year 2. All tasks have been fully performed and we will continue to maintain this activity throughout the time period of this award.
Research Purpose and Scope: We proposed to investigate how reactive oxygen species (ROS)-induced redox signaling pa thways i n breast can cer cells m ay co ntribute t o molecular m echanisms of ant iestrogen r esistance. Our hypothesis is that the conversion of breast tumors to a tamoxifen-resistant phenotype is associated with a progressive s hift t owards a pro-oxidant environment of cells as a r esult of ox idative s tress. W e postulate t hat excess ROS levels induce bot h CDC25A and change p27 phos phorylation promoting the loss of its inhibitory function and leading to antiestrogen resistance. We will investigate whether reducing the oxidative environment of breast cancer cells will restore the anti-proliferative action of tamoxifen and other antiestrogens by repressing CDC25A and altering p27 phosphorylation and restoring p27 function.
i) To test whether the ER+ antiestrogen resistant MCF-7
R , LY-2 and LCC-2 breast cancer cell lines regain sensitivity to the inhibitory growth effects of antiestrogen when oxidant levels are reduced by (b) raised or r estored l evels of GSH b y glutathione m odifiers or ove rexpressing G SH r estoring e nzymes; and (c) raised or restored levels of Trx by thioredoxin modifiers or overexpressing Trxn. To confirm and repeat the preliminary results it would require about 6 months.
Tasks to be accomplished in months 12-24 of this project were: Task 1 (Months 1-24): The following tasks are a continuation of experiments in year 1.
Anticipated Results: It is expected that redox signaling inhibition by pharmacological and genetic approaches restores the cell cycle inhibitory function of p27, reduces phosphorylation and enhances sensitivity of r esistant br east c ancer tum or c ells to tamoxifen or f ulvestrant. T hese s tudies w ould confirm tha t a daptation to higher ox idative s tate in breast carcinoma is not only causally linked to antiestrogen therapy resistance, but also elucidate the mechanism thereof.
Results for Task 1 (i) Subaim (b)
The purpose of this experiment was to determine the effect of glutathione modifiers on antiestrogen exposed breast cancer cells by looking at p27 expression and p27 phosphorylation.
We determined the effect of GSH modifiers Nacetylcysteine (NAC) and Ebselen on the protein level of p27 i n LY2 (Tamoxifen resistant) breast cancer c ells ex posed to antiestrogens. As s hown in Fig. , tamoxifen e xposed LY2 cells overexpressing catalase s howed an increase i n the p27 l evel. Both NAC and Ebselen showed a change in p27 levels compared to control. This data supports the ove rall h ypothesis b ecause i t s hows t hat p27 l evels a re r estored w hen e xposed t o t amoxifen. T hus, t he
Results:
increase in p27 levels suggest that b y d ecreasing the ox idant state of ant iestrogen resistant breast canc er cells restores redox s ignaling of p27 b y t amoxifen. The inc rease in p27 levels mos t like ly w ill inhibit c yclin dependent kinase activity and ultimately contribute to the suppression of the cell cycle.
Since t he activity of p2 7 i s r egulated b y degradation, we de termined the ef fect o f GSH m odifiers NAC a nd Ebselen on phosphorylation of p27 at threonine-187. Threonine 187 phosphorylation is known to target p27 for proteolytic degradation. The purpose of these experiments was determine the effects of NAC and Ebselen had on p27 degradation via Thr 187.
Anticipated Results:
We ex pect t o see a de crease i n Thr 187 phos phorylation of p27 i n c ells exposed t o NAC and Ebselen. Fig. ? ?, T hreonine-187 l evels decreased from tamoxifen exposure in LY2 cells treated with Ebselen and N AC. This cor relates w ith the increase i n p27 l evels w e obs erved i n LY2 cells tha t regain their s ensitivity t o tamoxifen. The de crease in Thr-187 implies tha t r educing th e ox idant s tate of the cell prevents Thr-187 targeted degradation of p27. This increases t he l evels o f p27 in L Y2 cells e xposed t o tamoxifen which in turn inhibits cell cycle progression. These da ta p artly explain the r egained antiestrogen sensitivity o f LY2 cells to t amoxifen vi a r edox signaling tha t me diate pos t-translational modi fications of p27 which contribute to its stability.
Results: As s hown i n
It is known that Akt phosphorylates Thr 157 of p27 and this reduces the nuclear import activity of p27. If p27 is not i n t he nucleus, t hen it cannot i nhibit G1 regulators of the cell cycle. The purpose of this experiment was to determine the effects of GSH modifiers had on Thr-157 of p27.
Anticipated Results:
We ex pect t hat T hr-157 w ould either de crease or r emain the s ame i n LY2 cel ls exposed to GSH modifier Ebselen plus tamoxifen.
Results : As shown in Fig. ? ?, when comparing Ebselen treated LY2 cells to control the re is a decrease in T hr 157 from tamoxifen exposure. The decrease in Thr-157 implies that p27 is more likely to be imported into the nucleus w here it w ill a ct to inhibit c yclin dependent kinases contributing to inhibition of the cell cycle. This increase i n nu clear p27 import w ould be i n l ine w ith our h ypothesis a nd s upport our c olony a ssay da ta; showing tha t a ntiestrogen resistant LY2 cells ar e inhibited by tamoxifen when exposed to ROS modifiers that reduce the oxidant state of the cell.
• The purpose of this experiment was to explore the role of thioredoxin reductase 2 (TrxR2) on tamoxifen resistant c ells. Our h ypothesis invol ves the r ole of r eactive ox idative s pecies ( ROS) in tamoxifen resistance in breast cancer, and thus we are altering the oxidative state of tamoxifen resistant breast cancer cells through increasing the expression of TrxR2. This, in turn reduces the antioxidant thioredoxin 2 to its active f orm. We want to s how t hat an i ncrease i n r educed m itochondrial t hioredoxin, t hrough t he overexpression of T rxR2, w ill r estore t he growth-inhibitory a ctions of tamoxifen in LCC2 (tamoxifen resistant) breast cance cells, and thus decrease colony growth in soft agar.
Results for Task 1 (i) Subaim (c)
Anticipated Results: While LCC2 cells normally grow t umors i n s oft a gar i n t he presence o f t amoxifen, we would e xpect t hat t he ove rexpression of R OS m odifier T rxR2 would c ause t amoxifen t o r egain i ts growth inhibitory effects in this antiestrogen resistant cell line.
As shown he re i n Fig. 1 (Representative phot o f rom t hree i ndependent e xperiments); w e s ee a cons istent reduction i n LCC2 colony growth in cells overexpressing. Conclusions f rom thi s e xperiment is tha t ROS generated from t amoxifen treatment i s ne cessary for t he growth i nhibition of a ntiestrogen s ensitive br east cancer c ells. T he da ta i n F ig. 1 s upports our h ypothesis be cause t he manipulation of t he ox idant s tate of antiestrogen resistant c ells, increased their s ensitivity to the growth inhibitory e ffects of ta moxifen. T hus, i t appears that antiestrogen resistant breast cancer cells have adapted to a higher level of oxidant stress which can be reversed by the overexpression of thioredoxin.
Task 1 (iii) Subaims a-f:
1. To determine w hich cell c ycle regulators are cr itical t o cell c ycle e ffects of r edox m anipulations, after cell treatments with ROS modifiers and antiestrogen.
(Months 13-24)
• The purpose of this experiment was to determine the effect of ROS modifiers on antiestrogen exposed breast cancer cells by looking at G1 regulators by RT-PCR (c-MYC, Cyclin D1 and the Cdk2 activating phosphatase, CDC25A) and western analysis (cyclins E, D and A, Cdk2, 4 and 6, and p21 and p27).
Results for Task 1 (iii) Subaim (a)
Anticipated Results: It is expected that redox signaling inhibition by pharmacological and genetic approaches restores t he c ell c ycle i nhibitory function of p27, r educes C DC25A e xpression a nd e nhances s ensitivity of resistant breast cancer tumor cells to tamoxifen or fulvestrant. These studies would confirm that adaptation to higher oxidative state in breast carcinoma is not only causally linked to antiestrogen therapy resistance, but also elucidate the mechanism thereof.
Results:
We first determined the effect of ROS modifiers catalase and MnSOD had on the protein level of p27 in LCC2 (Tamoxifen resistant) breast cancer cells exposed to antiestrogens. As shown in Fig. , tamoxifen exposed LCC2 cells overexpressing catalase showed an increase in the p27 l evel. Overexpression of MnSOD showed a more pronounced i ncrease i n p27 l evels compared t o control. T his da ta s upports t he ove rall h ypothesis be cause i t shows that p27 l evels are restored when exposed to tamoxifen. Thus, the increase in p27 l evels suggest that by decreasing t he ox idant s tate of ant iestrogen r esistant br east c ancer c ells r estores r edox s ignaling of p27 b y tamoxifen. The increase in p27 levels most likely will inhibit c yclin dependent kinase activity and ultimately contribute to the suppression of the cell cycle.
We have yet to complete the RT-PCR of cell cycle genes. We could not complete this task because one of our pre-doctoral s tudents changed f rom the PhD t o MPH program. We h ave ove rcome challenge this b y hiring a Post-Doc (Dr. Alok Deoraj) in place of her.
p27 associates with cyclin and cyclin-dependent kinase complexes to inhibit their kinase activity and contribute to the control of cell proliferation. p27 is phosphorylated on many sites, including threonine 187, in vivo , with the pr edominant phosphorylation s ite be ing s erine 10. T he e xtent of s erine 10 phos phorylation by pr olinedirected kinase is markedly increased in cells in the G0-G1 phase of the cell cycle compared to cells in the S or M pha se. Therefore the purpose of these experiments was t o determine w hether t he phosphorylation of p27 w as be ing m odulated b y overexpressing catalase (an H2O2 scavenger) and MnSOD (a superoxide radical scavenger).
Anticipated Results:
We ex pect t o s ee an increase i n S erine 10 phosphorylation in cells overexpressing catalase and/or MnSOD.
Results :
As s hown i n Fig. ? ?, both catalase and MnSOD ove rexpressing LCC2 c ells ( Tamoxifen resistant) s how an i ncrease i n S er 10 phosphorylation w hen e xposed t o tamoxifen. Since S er 10 phos phorylation i s know n t o increase t he pr otein s tability of p27, t his da ta supports our previous findings that p27 l evels are increased reversing t he antiestrogen resistance o f LCC2 c ells. O ur d ata supports our h ypothesis because a n i ncrease i n S er 10 of p27 w ould stabilize p27 pr otein r esulting i n a n i ncrease i n p27 l evels t hat w ould account f or t he r egained sensitivity o f a ntiestrogen resistant LCC2 cells have to Tamoxifen.
Since t he activity of p27 i s r egulated by degradation, we determined the effect of CAT and MnSOD ove rexpression ha d on p hosphorylation of p27 at t hreonine-187. T hreonine 18 7 phosphorylation i s kno wn t o t arget p27 f or proteolytic de gradation. The purpose of these experiments was determine t he ef fects of C AT and M nSOD ove rexpression ha d on p27 degradation via Thr 187.
Anticipated Results:
We expect to see a decrease in T hr 187 phos phorylation of p27 i n c ells overexpressing CAT and/or MnSOD. Fig. ? ?, T hreonine-187 levels de creased from t amoxifen exposure i n LCC2 cells ove rexpressing C AT. T his correlates with t he i ncrease i n p2 7 l evels w e obs erved i n LCC2 cells tha t r egain their s ensitivity to tamoxifen. T he de crease i n T hr-187 i mplies t hat reducing the oxidant state of the cell prevents Thr-187 t argeted de gradation of p27. T his i ncreases the levels of p27 in LCC2 cells exposed to tamoxifen which in turn inhibits c ell c ycle progression. In a ddition, w e obs erved a s imilar decrease i n Thr-187 i n t he LCC2 c ells overexpressing MnSOD (Fig. ??) . Together these results a re c onsistent with our pr evious da ta showing an increase of p27 in tamoxifen exposed LCC2 c ells ove rexpressing a ntioxidant e nzymes catalase ( CAT) and MnSOD. These d ata pa rtly explain the r egained antiestrogen s ensitivity o f LCC2 cells to tamoxifen via redox signaling that mediate pos t-translational m odifications of p27 which contribute to its stability.
Results: As s hown i n
It i s know n t hat A kt phos phorylates T hr 157 of p27 a nd t his r educes t he nuc lear i mport activity of p27. If p27 is not in the nucleus, then it cannot inhibit G 1 regulators of the cell cycle. The purpose of this experiment was to determine the effects of ROS modifiers had on Thr-157 of p27.
Anticipated Results:
We ex pect t hat T hr-157 would either de crease or r emain the s ame i n LCC2 cells overexpressing C AT and/or M nSOD when exposed to tamoxifen. Fig. ? ?, when c omparing CAT ove rexpressing LCC2 c ells t o t he ve ctor control t here i s no c hange i n T hr 157 f rom tamoxifen e xposure. H owever, we di d s how a decrease in T hr-157 of p27 w hen LCC2 c ells were ex posed to the che mical ant ioxidant ebselen. The decrease in Thr-157 implies that p27 is m ore l ikely t o be i mported i nto t he nuc leus where it w ill a ct to inhibit c yclin dependent kinases c ontributing t o i nhibition of t he c ell cycle. This increase in nuclear p27 i mport would be i n l ine w ith our h ypothesis a nd s upport our colony assay da ta; s howing t hat a ntiestrogen resistant LCC2 cells a re inhi bited by ta moxifen when e xposed t o R OS modifiers t hat reduce t he oxidant state of the cell.
Results : As s hown i n

Results for Task 1 (iii) Subaim (c):
• The purpose of this experiment was t o e xplore t he r ole of T rxR2 on D NA s ynthesis of t amoxifen resistant cells. As with the previous experiment, we are altering the oxidative state of tamoxifen resistant breast c ancer c ells t hrough i ncreasing t he e xpression of T rxR2. T his, i n t urn r educes t he a ntioxidant thioredoxin 2 to its active form, and reduces the oxidative state of the cells.
We w ill al so assay t he cell c ycle p rofile b y flow cytometry after BrdU pulse labeling and propodium iodide staining.
Anticipated:
Since tamoxifen is known to increase the oxidative state of breast cancer cells, an increase in reduced mitochondrial thioredoxin, through the overexpression of thioredoxin reductase 2, should restore the growth-inhibitory actions of tamoxifen in LCC2 (tamoxifen resistant) breast cancer cells, and thus decrease DNA synthesis.
As s hown i n Fig. ? ?, the a ntiestrogen resistant LCC2 breast can cer cells nor mally grow i n t he presence of tamoxifen, however, in cells overexpressing TrxR2 we observed the LCC2 cells to regain their sensitivity to the growth inhibitory effects of tamoxifen. There was a 33% decrease in DNA synthesis in TrxR2 overexpressing cells exposed to tamoxifen indicating that when the oxidative state of tamoxifen resistant cells is reduced, the tamoxifen inhibits DNA synthesis. Task 1 (iii) the following subaims b, d , e, f have not been completed (b) We will assay cyclin-Cdk complexes for activity and associated Cdk2 inhibitors, p27 and p21. (d) p27 phosphorylation will be assayed by 2D-phosphopeptide mapping. (e) The roles of putative redox responsive p27 phos phorylation sites will be investigated using phosphomutant p27 alleles. (f) p27's assembly function for cyclin D1-cdk4 or reduced ability to bind and inhibit cyclin E-cdk2 will also be assayed.
CHALLENGES AND DIFFICULTIES ENCOUNTERED.
Task 2 (Months 13-24): have not been completed 2. To test whether persistant oxidant generation abrogates antiestrogen action in sensitive cells through effects on cell cycle regulators and in particular on p27. In order to complete this task, we need to address following questions i) To test if pro-oxidative manipulations increase G1 progression, stimulate a more rapid cell cycle proliferation by inc reasing the le vels and activities of G1 cyclin E a nd A -Cdk2, a nd of t he C dk2 activating p hosphatase, Cdc25A a nd b y p romoting de gradation of t he C dk2 i nhibitors, p21 a nd p27 or t heir m islocalization i n the cytoplasm. ii) T o determine tha t th ese c ells tr eated with pro-oxidant pl us a ntiestrogen if the y have be come r esistant to antiestrogen-mediated G1 arrest can be m odified b y concurrent t reatment w ith ROS i nhibitors. a) T o analyze the expression of G1 genes (c-MYC, Cyclin D1 and CDC25A) by real time RT-PCR, and assay cyclins D, E and A, t heir Cdk l evels a nd c yclin-Cdk-Cdk i nhibitor c omplexes a nd ki nase a ctivities i n a ddition t o c ell c ycle profile by flow cytometry. b) To assay the phosphorylation, immunolocalization of p27 and its Cdk2 inhibitory function after the redox manipulations with or without antiestrogens.
Training:
Two o f our p re-doctoral t rainees are progressing s atisfactorily w hile one t rainee h as h ad difficulty with both didactic cour sework as w ell as r esearch performance. We c ould not c omplete some of t he tasks because one o f our pr e-doctoral s tudents changed from the PhD t o M PH pr ogram. We ha ve o vercome the challenge by hiring a Post-Doc (Dr. Alok Deoraj) in place of her.
Research
• Showed that overexpression of ROS modifiers Trx, Catalase, MnSOD in the Tamoxifen resistant breast cancer cell line LCC2 restored sensitivity to growth inhibition by tamoxifen.
: Even t hough m ost of the research techniques ar e r outinely performed in t he P I's and C o-PI's laboratories a t F IU, t he pre-doctoral t rainees ne ed to become f amiliar w ith t hese t echniques a nd standardize them. However, finding a post-doc took several months. And once hired it takes time to orient the post-doc to the research project. Furthermore, mastering new techniques can take time for a pre-doctoral student, which has slowed dow n pr ogress on m easuring c yclin c omplex a ctivity a nd 2 D ph osphopeptide m apping. However, w e have overcome these difficulties and we are working at full capacity to complete the research proposed in Year 2. Still the MCF-7R cell line is not available from Dr. Slingerland's lab due to fungal infection so we have only reported progress using two antiestrogen resistant cells LY-2 and LCC-2. The lack of progress from one of the pre-doctoral trainees has also slowed down research accomplishments, but we have overcome this by hiring a new post-doc as described in the training section.
KEY RESEARCH ACCOMPLISHMENTS
• Showed that the mechanism of regained antiestrogen sensitivity of LCC2 to tamoxifen is mediated by redox sensitive phosphorylation of p27 at Ser-10, Thr-187, and Thr-157.
